Ministry of Foreign Affairs Strongly Condemns and Denounces Lebanese Foreign Minister's Disgraceful Insults against Saudi Arabia, its People, and GCC Countries    Saudi Arabia Wins WSIS Prize 2021    Saudi Stock Exchange Main Index Ends Trading Higher at 10,423.51 Points    Jordan Records 1,174 New COVID-19 Cases    Bahraini Foreign Minister Receives Phone Call from His US Counterpart    Al-Asoumi commends Saudi Arabia's support for Sudan    Dr. Al-Sheikh affirms Saudi Arabia's commitment to achieve sustainable development    EAD continues to implement plans to protect Al Wathba Fossil Dunes    India logs record number of Covid deaths as caseload hits 25 million    Indian Navy hunts for 80 missing at sea after devastating cyclone    Russia Reports 8,183 New COVID-19 Cases, 364 Deaths    OIC's IPHRC holds Israel fully accountable for random killing of innocent Palestinians    Museums Commission to host a virtual concert on International Museum Day    Saudi Press: Social Responsibility Leads Next Phase of Controlling Pandemic    Prosthetics Center in Aden Continues to Provide Services with KSRelief's Support    Biden expresses 'support' for Gaza ceasefire in call with Netanyahu    King Salman reviews bilateral ties with Bahraini king in phone call    US secretary of state, UAE foreign minister review developments in Israel, Palestine Blinken speaks to EU's Borrell to coordinate efforts to ease Mideast tensions    Museums Commission to host a virtual concert on International Museum Day    Working for 55 hours or more in a week health hazard: WHO Long working hours killing 745,000 people a year, study finds    FDIs into UAE grow by 44.2 percent in 2020    First Flight Flown Form Hail International Airport Heading to Cairo    Al-Attiyah guides Toyota to victory in Andalucia Rally    Saudi Arabia Ranks 5th Worldwide, in Terms of Mobile Internet's Speed    Madinah airport ready for resumption of international flights    STA brings the best of Saudi to Arabian Travel Market 2021    Ensure digital technologies are 'a force for good' — Guterres    Gardening is 'political' says Irish celebrity horticulturist    Only 'coronavirus immune' citizens over 18 years of age can travel to Bahrain    Tyson Fury confirms date for long-awaited fight against Anthony Joshua    Saudi Arabia to Take Part in the World Hypertension Day    Diego Maradona    Remarkable collection of Syrian art transcends horrors of war: Arte Arta Gallery    Champions League final 2021 moved from Istanbul to Porto's Estádio do Dragão    Tawakkalna Launches Registration Service to Donate Organs on its Website    From whom do we take Shariah? How do we get legitimacy?    Sheikh Salman Al Khalifa: Saudi Football Association is distinguished and professional    Saudi Rower Hussain Alireza sets for 2021 Tokyo Olympics qualifiers    Asian Handball Championships' Draw to Take Place in Jeddah on Saturday    President of Union of Arab Football Associations Meets with Heads of FIFA, AFC and CAF    Business Lady Led Saudi World Competitiveness Edge, in Banana Planting    Welcome to beautiful Ramadan customs    Vaccination does not invalidate fasting, says UAE Fatwa Council    It is high time to correct wrong concepts about women's status    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





EU publishes AstraZeneca contract amid coronavirus vaccine row
Published in The Saudi Gazette on 29 - 01 - 2021

The European Union published its coronavirus vaccine contract with AstraZeneca amid an ongoing row over delays to vaccine deliveries.
It came after European Commission President Ursula von der Leyen weighed in on the dispute with the pharmaceutical company, telling a German radio station on Friday that there is "no plausible explanation" for its delay in supplying its vaccine to the EU.
The European Medicines Agency is expected on Friday to authorize the use of the vaccine AstraZeneca developed with Oxford University. It would be the third cleared for use in the EU, after the BioNTech-Pfizer and Moderna vaccines.
The European Commission has been locked in a dispute with the British-Swedish pharmaceutical company since it said it would deliver far smaller than expected supplies to EU member nations.
The European Union is looking at legal ways to guarantee the delivery of all the COVID-19 vaccine doses it bought from AstraZeneca and other drugmakers.
The Commission President increased the pressure on AstraZeneca in her interview, reiterating the EU's view that the contract is unambiguous and its rejection of the company's reasons for cutting planned supplies by at least 60 percent.
"There are binding orders and the contract is crystal clear," she said.
Von der Leyen dismissed the claims by AstraZeneca — which has blamed "glitches" in production — that under its contract with the EU it was only obliged to make "best efforts" to deliver supplies.
"(The phrase) 'best efforts' meant as long as it was not clear whether they (AstraZeneca) can develop a vaccine. We have now passed that time. The vaccine is here."
She added that the Commission wanted to make the contract public. Later, the Commission did just that.
"We want to publish it today," she said. "This is business sensitive data, that's clear. But basically: we want to create transparency on these issues that I have just touched on. We know exactly what is in the contract, which is why it is important to us that it is now made public."
In a sign of the level of EU mistrust in AstraZeneca, on Thursday Belgian authorities inspected a factory in Belgium that is part of AstraZeneca's vaccine production chain. It followed a crisis meeting the previous evening between EU officials and the company which failed to resolve the issue.
Meanwhile, both AstraZeneca and the UK, which has already been using the vaccine, insist it is efficient in older adults. This follows doubt cast in Germany by the country's vaccination commission which declined to recommend its immediate use for people over 65.
EU to 'explore all options'
In a reply to a letter he received from four European government leaders, EU Council President Charles Michel said the EU "should explore all options and make use of all legal means and enforcement measures at our disposal," if negotiations with drug companies don't yield satisfaction.
AstraZeneca said last week that it planned to cut initial deliveries in the EU from the scheduled 80 million doses for the first quarter of the year to 31 million doses. The company cited reduced yields from its manufacturing plants in Europe, but the EU suspects doses produced in Europe have been directed elsewhere.
Michel said the use of the EU treaties would allow the EU and member states to take "appropriate urgent measures, to ensure effective vaccine production and supply for our population".
The European Commission also plans to new rules strengthening the control of vaccine exports to ensure the doses it bought are delivered to the bloc's residents.
The dispute highlights the tension over vaccine supplies as Europe struggles to roll out inoculation programs against the coronavirus.
AstraZeneca and UK refute German claims
The UK and AstraZeneca hit back on Thursday at the draft recommendation in Germany to restrict the use of the vaccine only to people aged 18-64 for now. The country's vaccination advisory committee cited what it said was insufficient data to judge its effectiveness for older people.
"Our own authorities have made it very clear that they think the Oxford AstraZeneca vaccine is very good and efficacious," said British Prime Minister Boris Johnson. "The evidence that they've seen, that they've supplied, is that they think that it is effective across all age groups and provides a good immune response across all age groups."
"The latest analyses of clinical trial data for the AstraZeneca/Oxford COVID-19 vaccine support efficacy in the over 65 years age group. We await a regulatory decision on the vaccine by the EMA in the coming days," an AstraZeneca spokesperson said.
Germany's health minister has stressed that a final decision will not be made until after Friday's EMA meeting. — Euronews


Clic here to read the story from its source.